Observational Health Data Sciences and Informatics

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
=====Characterization of Oral Antibiotics for Acne Treatment======

**Objective:** 
Aim 1: Characterize the international distribution of oral antibiotic use for acne in the pediatric and young adult population ages 12 to 20.
Aim 2: Characterize the international distribution of oral antibiotic use for acne in the adult population ages 21 to 40.

//**Rationale:** //
Acne is a common and disabling medical condition, particularly amongst adolescents and young adults.[1]  According to the Global Burden of Disease Study 2016, acne is the most disabling skin condition worldwide, responsible for 0.28% of global burden from all diseases.[2]  In addition to physical disfigurement, the profound psychosocial effects of acne have been recognized for over half a century.[3]  Guidelines established by the American Academy of Dermatology recommend minimizing the duration of systemic antibiotics for the management of acne ideally to 3-4 months and no longer than 6 months in order to decrease risk of resistance.[1]  A recent systematic review demonstrated that over 50% of P. acnes strains are reported as resistant in all major regions of the world.[4]  In addition to promoting resistance, long-term oral antibiotic use has been associated with a number of adverse events including microbiome disruption and pharyngitis, as well as possible associations with inflammatory bowel disease and obesity.[5]  Despite these adverse effects, oral antibiotics are often prescribed for acne for longer durations than acne guidelines recommend.[5]  A large retrospective cohort study of teenagers in the UK revealed that 29% of antibiotic courses prescribed by general practitioners exceeded 6 months in duration.[5]  A similar retrospective cohort study of teenagers and young adults in the US found that 18% of antibiotic courses exceeded 6 months.[6]  Our study will investigate oral antibiotic use for acne over the last ten years across the globe in both pediatric/young adult and adult populations.  OHDSI network evidence will identify areas of the globe most in need of improving guideline concordance//.//

**Project Lead(s):**  //Robert P. Dellavalle, Lisa M. Schilling//

**Coordinating Institution(s):** //University of Colorado School of Medicine//

**Additional Participants:** // //Chante Karimkhani: ck2525@caa.columbia.edu  
Chandler Rundle: chandler.rundle@gmail.com
Megan Branda: MEGAN.BRANDA@cuanschutz.edu
John Barbieri: john.barbieri@uphs.upenn.edu
Chris Knoll: cknoll1@its.jnj.com
David Margolis: margo@mail.med.upenn.edu 
Patrick Ryan: ryan@ohdsi.org 
Martijn Schuemie: m.schuemie@erasmusmc.nl 
Jonathan Silverberg: JonathanISilverberg@gmail.com 
Dylan Ray: DYLAN.RAY@cuanschutz.edu
Sara Deakyne: Sara.DeakyneDavies@childrenscolorado.org

**Full Draft Protocol:** //Please provide any comments or suggestions.//
[[https://docs.google.com/document/d/1LnugUQrloOn-3cZJDdTpgVYEsynu7SBztFtjzjAuEDE/edit]]

**Initial Proposal Date:** //25 August 2016//

**Launch Date:** //  //

**Study Closure Date:** // //

**Forum Discussion Thread**

http://forums.ohdsi.org/t/ohdsi-study-concordance-with-antibiotic-treatment-guidelines-for-acne/1703
Observational Health Data Sciences and Informatics

User Tools

Site Tools

Page Tools
